Asakura M - Search Results

1

Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction?

Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H, Kitakaze M; ABC investigators. Asakura M, et al. Cardiovasc Drugs Ther. 2017 Aug;31(4):401-411. doi: 10.1007/s10557-017-6740-3. Cardiovasc Drugs Ther. 2017. PMID: 28779371 Clinical Trial.

2

Nifedipine-induced coronary vasodilation in ischemic hearts is attributable to bradykinin- and NO-dependent mechanisms in dogs.

Kitakaze M, Asanuma H, Takashima S, Minamino T, Ueda Y, Sakata Y, Asakura M, Sanada S, Kuzuya T, Hori M. Kitakaze M, et al. Among authors: asakura m. Circulation. 2000 Jan 25;101(3):311-7. doi: 10.1161/01.cir.101.3.311. Circulation. 2000. PMID: 10645928

3

Protein tyrosine kinase is not involved in the infarct size-limiting effect of ischemic preconditioning in canine hearts.

Kitakaze M, Node K, Asanuma H, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Kuzuya T, Hori M. Kitakaze M, et al. Among authors: asakura m. Circ Res. 2000 Aug 18;87(4):303-8. doi: 10.1161/01.res.87.4.303. Circ Res. 2000. PMID: 10948064

4

Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.

Sanada S, Kitakaze M, Papst PJ, Asanuma H, Node K, Takashima S, Asakura M, Ogita H, Liao Y, Sakata Y, Ogai A, Fukushima T, Yamada J, Shinozaki Y, Kuzuya T, Mori H, Terada N, Hori M. Sanada S, et al. Among authors: asakura m. Circulation. 2001 Aug 7;104(6):705-10. doi: 10.1161/hc3201.092216. Circulation. 2001. PMID: 11489779

5

Role of cellular acidosis in production of nitric oxide in canine ischemic myocardium.

Kitakaze M, Node K, Takashima S, Asanuma H, Asakura M, Sanada S, Shinozaki Y, Mori H, Sato H, Kuzuya T, Hori M. Kitakaze M, et al. Among authors: asakura m. J Mol Cell Cardiol. 2001 Sep;33(9):1727-37. doi: 10.1006/jmcc.2001.1435. J Mol Cell Cardiol. 2001. PMID: 11549351

6

Nifedipine limits infarct size via NO-dependent mechanisms in dogs.

Asanuma H, Kitakaze M, Funaya H, Takashima S, Minamino T, Node K, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Kuzuya T, Tada M, Hori M. Asanuma H, et al. Among authors: asakura m. Basic Res Cardiol. 2001 Sep;96(5):497-505. doi: 10.1007/s003950170032. Basic Res Cardiol. 2001. PMID: 11605997

7

cDNA array hybridization reveals cardiac gene expression in acute ischemic murine hearts.

Kitakaze M, Asakura M, Sakata Y, Asanuma H, Sanada S, Kuzuya T, Miyazaki J, Takashima S, Hori M. Kitakaze M, et al. Among authors: asakura m. Cardiovasc Drugs Ther. 2001 Mar;15(2):125-30. doi: 10.1023/a:1011118828197. Cardiovasc Drugs Ther. 2001. PMID: 11669405

8

Benidipine, a long-acting Ca channel blocker, limits infarct size via bradykinin- and NO-dependent mechanisms in canine hearts.

Asanuma H, Kitakaze M, Node K, Takashima S, Sakata Y, Asakura M, Sanada S, Shinozaki Y, Mori H, Tada M, Kuzuya T, Hori M. Asanuma H, et al. Among authors: asakura m. Cardiovasc Drugs Ther. 2001;15(3):225-31. doi: 10.1023/a:1011964222712. Cardiovasc Drugs Ther. 2001. PMID: 11713890

9

Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy.

Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S. Asakura M, et al. Nat Med. 2002 Jan;8(1):35-40. doi: 10.1038/nm0102-35. Nat Med. 2002. PMID: 11786904

10

[Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart].

Ogita H, Node K, Asanuma H, Sanada S, Takashima S, Asakura M, Kitakaze M, Hori M. Ogita H, et al. Among authors: asakura m. J Cardiol. 2002 Jan;39(1):55-6. J Cardiol. 2002. PMID: 11828800 Free article. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

428 results

Search Page

Filters